Funded by the Centers for
Disease Control and Prevention
- Lead-in phase: Refers to the initial (typically 4-week) period of HCV treatment where pegylated interferon and ribavirin are started before the addition of the third agent. Boceprevir, for example, requires a 4-week lead-in based on clinical trial design. The lead-in provides the advantage of assessing interferon responsiveness and likelihood of subsequent treatment response in treatment-naïve individuals.